Zacks Investment Research downgraded shares of Adamas Pharmaceuticals (NASDAQ:ADMS) from a buy rating to a hold rating in a report issued on Wednesday, Zacks.com reports.

According to Zacks, “Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company’s portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. “

Other equities analysts have also recently issued reports about the company. Piper Jaffray Companies set a $23.00 price objective on Adamas Pharmaceuticals and gave the company a buy rating in a research note on Tuesday, March 5th. HC Wainwright set a $40.00 price objective on Adamas Pharmaceuticals and gave the company a buy rating in a research note on Tuesday, March 5th. Northland Securities restated a buy rating and set a $28.00 price objective on shares of Adamas Pharmaceuticals in a research note on Tuesday, March 5th. BidaskClub upgraded Adamas Pharmaceuticals from a sell rating to a hold rating in a research note on Monday, February 25th. Finally, ValuEngine upgraded Adamas Pharmaceuticals from a sell rating to a hold rating in a research note on Monday, April 1st. Two analysts have rated the stock with a sell rating, five have given a hold rating and four have given a buy rating to the stock. The company has an average rating of Hold and an average target price of $20.25.

NASDAQ ADMS opened at $4.99 on Wednesday. Adamas Pharmaceuticals has a 12-month low of $4.93 and a 12-month high of $29.49. The company has a debt-to-equity ratio of 2.00, a current ratio of 7.03 and a quick ratio of 6.86. The firm has a market capitalization of $137.39 million, a P/E ratio of -1.02 and a beta of 1.35.

Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its quarterly earnings data on Thursday, May 9th. The specialty pharmaceutical company reported ($1.08) earnings per share for the quarter, beating the consensus estimate of ($1.13) by $0.05. Adamas Pharmaceuticals had a negative return on equity of 122.40% and a negative net margin of 291.22%. The business had revenue of $11.67 million for the quarter, compared to analysts’ expectations of $12.78 million. On average, sell-side analysts expect that Adamas Pharmaceuticals will post -3.87 earnings per share for the current year.

In other news, CEO Gregory T. Went sold 6,319 shares of Adamas Pharmaceuticals stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $7.99, for a total transaction of $50,488.81. Following the sale, the chief executive officer now directly owns 176,291 shares in the company, valued at approximately $1,408,565.09. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Over the last 90 days, insiders have sold 8,361 shares of company stock worth $66,816. Company insiders own 24.90% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Arbitrage SA bought a new stake in shares of Adamas Pharmaceuticals during the 1st quarter worth $33,000. First Mercantile Trust Co. raised its stake in shares of Adamas Pharmaceuticals by 43.2% during the 4th quarter. First Mercantile Trust Co. now owns 5,765 shares of the specialty pharmaceutical company’s stock worth $49,000 after purchasing an additional 1,740 shares during the period. PNC Financial Services Group Inc. bought a new stake in shares of Adamas Pharmaceuticals during the 1st quarter worth $43,000. Advisor Group Inc. raised its stake in shares of Adamas Pharmaceuticals by 252.0% during the 4th quarter. Advisor Group Inc. now owns 6,300 shares of the specialty pharmaceutical company’s stock worth $54,000 after purchasing an additional 4,510 shares during the period. Finally, Jefferies Group LLC bought a new stake in shares of Adamas Pharmaceuticals during the 1st quarter worth $107,000. Institutional investors own 84.76% of the company’s stock.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.

Featured Article: What is Depreciation?

Get a free copy of the Zacks research report on Adamas Pharmaceuticals (ADMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.